X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Usual Pharma Compliance Issues Noted In FDA Warning Letters

    First Gene Treatment For Early Bladder Cancer Okayed By FDA

    Hemophilia Gene Therapy Now Backed By European Regulators

    WHO Revises Treatment Recommendations For Drug-Resistant TB

    By 2032, The Alzheimers Treatments Market Will Be $6.8 Bn

    New Zealand Health Agencies Aim To Improve Clinical Trials

    Canadian And US Developers To Test Psychedelic Drugs In UK

    Future Biotech Platforms Likely To Depend Primarily On Urine

    NICE Methodology Raises Concerns For Kidney Research UK

    As Per The WHO Assessment, AMR Monitoring Must Be Enhanced

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Usual Pharma Compliance Issues Noted In FDA Warning Letters

    First Gene Treatment For Early Bladder Cancer Okayed By FDA

    Hemophilia Gene Therapy Now Backed By European Regulators

    WHO Revises Treatment Recommendations For Drug-Resistant TB

    By 2032, The Alzheimers Treatments Market Will Be $6.8 Bn

    New Zealand Health Agencies Aim To Improve Clinical Trials

    Canadian And US Developers To Test Psychedelic Drugs In UK

    Future Biotech Platforms Likely To Depend Primarily On Urine

    NICE Methodology Raises Concerns For Kidney Research UK

    As Per The WHO Assessment, AMR Monitoring Must Be Enhanced

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development FDA Approvals

First Gene Treatment For Early Bladder Cancer Okayed By FDA

Content Team by Content Team
20th December 2022
in FDA Approvals, News
Usual Pharma Compliance Issues Noted In FDA Warning Letters

The first gene therapy for non-muscle invasive bladder cancer (NMIBC) in individuals with high-risk carcinoma in situ (CIS) with or without papillary tumours has been licenced by the US Food and Drug Administration (FDA) as Adstiladrin (nadofaragene firadenovec-vncg). Adstiladrin, a non-replicating adenoviral vector-based therapy, offers a novel therapeutic option for patients who have high-risk, non-muscle-invasive bladder cancer that is non-responsive to BCG therapy, according to FDA Center for Biologics Evaluation and Research director, Dr. Peter Marks, PhD.

Patients with high-risk NMIBC, particularly those with CIS, are often treated and cared for by removing the tumour and administering the BCG vaccine to lower the likelihood that the disease will return. Patients who develop a condition that is resistant to BCG have few viable therapy choices available.

An elevated risk of death or a disease-worsening event is linked to the inability to achieve a complete response (CR), or the removal of all indications of cancer as observed on cystoscopy, biopsied tissue, and urine. Without therapy, the cancer has the potential to spread throughout the body, invade healthy tissues, and harm organs.

Clinical Investigation of Astladrin

A multicenter clinical study involving 157 patients who had high-risk BCG-unresponsive NMIBC, 98 of whom had BCG-unresponsive CIS with or without papillary tumours and were examined for response, evaluated the safety and efficacy of Adstiladrin.

Using a urinary catheter, patients were treated with Adstiladrin once every three months for up to 12 months, or until there was intolerable treatment toxicity or recurrent high-grade NMIBC. 51% patients in total had a CR. 9.7 months on average passed before a response was made. 46%  of the responding patients had stayed on CR for at least a year.

The most frequent adverse reactions were urinary urgency, haematuria (blood in the urine), weariness, bladder spasms, bladder discharge, cold, temperature, and painful urination. Adstiladrin should not be ingested by anyone with weakened or suppressed immune systems, according to the FDA.

Previous Post

Hemophilia Gene Therapy Now Backed By European Regulators

Related Posts

FDA Approvals

Hemophilia Gene Therapy Now Backed By European Regulators

20th December 2022
Drug Development

WHO Revises Treatment Recommendations For Drug-Resistant TB

20th December 2022
Drug Development

By 2032, The Alzheimers Treatments Market Will Be $6.8 Bn

19th December 2022
News

The Pharmaceutical Market In 2023- Trends And Predictions

19th December 2022
Facilities & Operation

Quality Assurance Advances In Pharmaceutical Manufacturing

19th December 2022
IPR Data Management

6 Issues In Pharma-Biotech Patent Disputes To Watch In 2023

17th December 2022

Latest News

Usual Pharma Compliance Issues Noted In FDA Warning Letters
FDA Approvals

First Gene Treatment For Early Bladder Cancer Okayed By FDA

20th December 2022
FDA Approvals

Hemophilia Gene Therapy Now Backed By European Regulators

20th December 2022
Drug Development

WHO Revises Treatment Recommendations For Drug-Resistant TB

20th December 2022
Drug Development

By 2032, The Alzheimers Treatments Market Will Be $6.8 Bn

19th December 2022
News

The Pharmaceutical Market In 2023- Trends And Predictions

19th December 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In